Orsini and BridgeBio Collaboration: New Hope for Cardiomyopathy Patients with ATTRUBY™

Orsini and BridgeBio: A Promising Alliance in Patient Care

In a significant advance for patients suffering from cardiomyopathy due to transthyretin-mediated amyloidosis, Orsini Specialty Pharmacy has joined forces with BridgeBio to distribute ATTRUBY™ (acoramidis). This orally administered treatment is designed for adults with both wild-type and variant forms of the condition, a complex and often underdiagnosed disease that can lead to severe cardiovascular complications.

Understanding ATTR-CM

Transthyretin-mediated amyloidosis (ATTR-CM) is a type of heart disease caused by the accumulation of misfolded proteins, which can lead to cardiac dysfunction. As the disease progresses, it often results in heart failure, significantly impacting patients' quality of life and longevity. Recognizing the urgent need for effective therapies, the advent of ATTRUBY™ provides a critical option for managing this debilitating condition.

The drug acts as a stabilizer for the transthyretin protein, helping to prevent further cardiac damage and potentially reducing the risk of cardiovascular-related deaths and hospitalizations. With a stabilization rate of over 90%, ATTRUBY™ represents a new standard in care for patients with ATTR-CM.

Orsini's Commitment to Specialized Care

Since its inception in 1987, Orsini has been committed to enhancing the lives of patients suffering from rare diseases. Specializing in providing comprehensive and compassionate care, Orsini plays a pivotal role in the treatment landscape for patients with cardiomyopathy. The company has established its Cardiology Center of Excellence, enhancing its focus on cardiac conditions and ensuring dedicated support for patients receiving ATTRUBY™.

According to Darin DeCarlo, Orsini's Chief Growth Officer, this partnership with BridgeBio opens new avenues for delivering hope to patients. With a background of over five years supporting individuals with cardiomyopathy, Orsini is well-equipped to facilitate access to innovative therapies like ATTRUBY™.

Tailored Support from the Care Team

To optimize the experience for patients prescribed ATTRUBY™, Orsini has assembled a specialized ATTR-CM Care Team. This group is dedicated to providing personalized support, ensuring that patients understand their treatment, receive medication on time, and have access to essential resources. This hands-on approach aligns with Orsini's mission to guarantee that no patient is left behind.

Moreover, the care model focuses on individual patient interactions, aiming to empower patients in managing their condition effectively. Through comprehensive education and consistent follow-ups, the care team works to ensure that patients feel supported throughout their treatment journey.

A Forward-Looking Future

As Orsini begins distribution of ATTRUBY™, it represents not just a treatment, but also a collaborative effort to redefine the support available for patients with rare diseases. With BridgeBio's innovative approach and Orsini's commitment to specialty pharmacy solutions, this partnership could significantly alter the trajectory of ATTR-CM management.

The healthcare landscape is rapidly evolving, especially in the realm of rare diseases, and this collaboration exemplifies how strategic partnerships can lead to enhanced patient outcomes. For more information regarding the new treatment, patients can reach out to Orsini directly through their website or customer service channels.

In conclusion, the introduction of ATTRUBY™ into Orsini's offerings is a testament to the power of partnerships in healthcare, aiming to bring hope and healing to those affected by transthyretin-mediated amyloidosis. This collaboration marks a crucial step towards improving lives, one patient at a time.